Teva Slams Antitrust Claims In Azilect Patent Row

Law360, New York (February 21, 2013, 6:59 PM EST) -- Teva Pharmaceutical Industries Ltd. said its patent for its Parkinson’s disease drug Azilect is valid and would-be generic competitors are overreaching in claims that it broke antitrust laws to secure the patent through fraud and sham suits, according to a pretrial brief filed Wednesday in New Jersey federal court.

Teva slammed the antitrust and patent invalidity claims raised by generic drugmakers Watson Laboratories Inc., Mylan Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Ltd. and Apotex Corp., saying there is clear evidence that they infringed on Teva’s patent...
To view the full article, register now.